Baveno VII - Renewing consensus in portal hypertension
- PMID: 35120736
- PMCID: PMC11090185
- DOI: 10.1016/j.jhep.2021.12.022
Baveno VII - Renewing consensus in portal hypertension
Erratum in
-
Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].J Hepatol. 2022 Jul;77(1):271. doi: 10.1016/j.jhep.2022.03.024. Epub 2022 Apr 14. J Hepatol. 2022. PMID: 35431106 No abstract available.
Abstract
To expand on the work of previous meetings, a virtual Baveno VII workshop was organised for October 2021. Among patients with compensated cirrhosis or compensated advanced chronic liver disease (cACLD - defined at the Baveno VI conference), the presence or absence of clinically significant portal hypertension (CSPH) is associated with differing outcomes, including risk of death, and different diagnostic and therapeutic needs. Accordingly, the Baveno VII workshop was entitled "Personalized Care for Portal Hypertension". The main fields of discussion were the relevance and indications for measuring the hepatic venous pressure gradient as a gold standard, the use of non-invasive tools for the diagnosis of cACLD and CSPH, the impact of aetiological and non-aetiological therapies on the course of cirrhosis, the prevention of the first episode of decompensation, the management of an acute bleeding episode, the prevention of further decompensation, as well as the diagnosis and management of splanchnic vein thrombosis and other vascular disorders of the liver. For each of these 9 topics, a thorough review of the medical literature was performed, and a series of consensus statements/recommendations were discussed and agreed upon. A summary of the most important conclusions/recommendations derived from the workshop is reported here. The statements are classified as unchanged, changed, and new in relation to Baveno VI.
Keywords: Cirrhosis; decompensation; diagnosis; recommendations; treatment.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest None relating to this manuscript. JB has been a consultant for Zydus, Surrozen and Actelion. TR is a consultant for and/or receives research support from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Philips, Pliant Pharmaceuticals, Roche, and Siemens. RdF, CR and GGT have no disclosures to report. Please refer to the accompanying ICMJE disclosure forms for further details.
Figures
Comment in
-
Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma.J Hepatol. 2022 Aug;77(2):566-567. doi: 10.1016/j.jhep.2022.02.004. Epub 2022 Feb 17. J Hepatol. 2022. PMID: 35182660 No abstract available.
-
Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.J Hepatol. 2022 Aug;77(2):567-568. doi: 10.1016/j.jhep.2022.04.029. Epub 2022 May 5. J Hepatol. 2022. PMID: 35526788 No abstract available.
-
Direct portal pressure gradient measurement in patients with porto-sinusoidal vascular disease.Dig Liver Dis. 2023 Jan;55(1):144-145. doi: 10.1016/j.dld.2022.10.013. Epub 2022 Nov 11. Dig Liver Dis. 2023. PMID: 36376232 No abstract available.
Similar articles
-
[Baveno VII - Renewing consensus in portal hypertension: personalized care for portal hypertension].Zhonghua Gan Zang Bing Za Zhi. 2022 Jan 20;30(1):21-29. doi: 10.3760/cma.j.cn501113-20220109-00010. Zhonghua Gan Zang Bing Za Zhi. 2022. PMID: 35152666 Chinese.
-
Evolving portal hypertension through Baveno VII recommendations.Ann Hepatol. 2024 Jan-Feb;29(1):101180. doi: 10.1016/j.aohep.2023.101180. Epub 2023 Nov 19. Ann Hepatol. 2024. PMID: 37984701 Review.
-
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.J Hepatol. 2024 Aug;81(2):248-257. doi: 10.1016/j.jhep.2024.03.005. Epub 2024 Mar 11. J Hepatol. 2024. PMID: 38479612
-
Utility of different Baveno criteria to detect esophageal varices irrespective of their size in patients with compensated cirrhosis.Indian J Gastroenterol. 2024 Jun;43(3):609-615. doi: 10.1007/s12664-023-01458-1. Epub 2023 Oct 16. Indian J Gastroenterol. 2024. PMID: 37840111
-
Non-invasive diagnosis of esophageal varices after Baveno VI.Turk J Gastroenterol. 2017 May;28(3):159-165. doi: 10.5152/tjg.2017.16744. Turk J Gastroenterol. 2017. PMID: 28492370 Review.
Cited by
-
Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.BMJ Open. 2024 Jul 11;14(7):e081623. doi: 10.1136/bmjopen-2023-081623. BMJ Open. 2024. PMID: 38991669 Free PMC article.
-
Liver stiffness (Fibroscan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease.Liver Int. 2023 Jan;43(1):90-99. doi: 10.1111/liv.15415. Epub 2022 Sep 27. Liver Int. 2023. PMID: 36050821 Free PMC article.
-
Application of Machine Learning Techniques to Assess Alpha-Fetoprotein at Diagnosis of Hepatocellular Carcinoma.Int J Mol Sci. 2024 Feb 7;25(4):1996. doi: 10.3390/ijms25041996. Int J Mol Sci. 2024. PMID: 38396674 Free PMC article.
-
Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion.Cancer Imaging. 2024 Jan 13;24(1):9. doi: 10.1186/s40644-024-00657-z. Cancer Imaging. 2024. PMID: 38217049 Free PMC article.
-
Guidelines for the Management of Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertension.J Clin Transl Hepatol. 2023 Dec 28;11(7):1565-1579. doi: 10.14218/JCTH.2023.00061. Epub 2023 Oct 17. J Clin Transl Hepatol. 2023. PMID: 38161497 Free PMC article.
References
-
- Burroughs AK, editor. Methodology and review of clinical trials in portal hypertension. Amsterdam, New York, Oxford: Excerpta Medical Congress Service N◦; 763; 1987.
-
- de Franchis R, Pascal JP, Ancona E, Burroughs AK, Henderson JM, Fleig W, et al. Definitions, methodology and therapeutic strategies in portal hypertension. A consensus development workshop. J Hepatol 1992;15:256–261. - PubMed
-
- de Franchis R Developing consensus in portal hypertension. J Hepatol 1996;25:390–394. - PubMed
-
- de Franchis R, editor. Portal Hypertension II. Proceedings of the second Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford: Blackwell Science; 1996.
-
- Spina GP, Arcidiacono R, Bosch J, Pagliaro L, Burroughs AK, Santambrogio R, et al. Gastric endoscopic features in portal hypertension: final report of a consensus conference. J Hepatol 1994;21:461–467. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources